P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia

Oncology Reports

Volumn 12, Issue 6, 2004, Pages 1201-1207

  Casale, F ^a   D'Angelo, V ^a   Addeo, R ^a   Caraglia, M ^a   Crisci, S ^a   Rondelli, R ^b   Di Tullio, M T ^a   Indolfi, P ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute lymphoblastic leukemia; Children; Multidrug resistance; P glycoprotein; Prognostic markers

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; TUMOR MARKER;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ARTICLE; BIOSYNTHESIS; CHILD; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MORTALITY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; P-GLYCOPROTEIN; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 16644372586     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.12.6.1201     Document Type: Article

References (33)

1. Dalton WS: Mechanisms of drug resistance in hematologic malignancies. Semin Hematol 34: 3-8, 1997.
2. Bradshaw DM and Arceci RJ: Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. J Clin Oncol 11: 3674-3690, 1998. (Pubitemid 28506783)
3. Lowenberg B and Sonneveld P: Resistance to chemotherapy in acute leukemia. Curr Opin Oncol 10: 31-35, 1998. (Pubitemid 28039239)
4. Shen DW, Cardarelli C, Hwang J, et al: Multiple drug resistance human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770, 1986. (Pubitemid 17208699)
5. Casale F, Addeo R, D'Angelo V, et al: Determination of the in vivo affects of prednisone on BCL-2 family protein expression in childhood acute lymphoblastic leukemia. Int J Oncol 22: 123-128, 2003.
6. Rothenberg ML, Mickley LA, Cole DE, et al: Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74: 1388-1395, 1989. (Pubitemid 19227452)
7. Goasguen JE, Dossot JM, Fardel O, et al: Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 81: 2394-2398, 1993. (Pubitemid 23127076)
8. Savignano C, Geromin A, Michieli M, et al: The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. Haematologica 78: 261-263, 1993. (Pubitemid 23357431)
9. Wattel E, Lepelley P, Merlat A, et al: Expression of the multidrug resistance P-glycoprotein in newly diagnosed adult acute lymphoblastic leukemia: absence of correlation with response to treatment. Leukemia 9: 1870-1874, 1995.
10. Marie JP, Legrand O, Perrot JY, et al: Measuring multidrug resistance expression in human malignancies: elaboration of consensus recommendations. Semin Hematol 34: 63-71, 1997. (Pubitemid 28032421)
11. Beck WT, Grogan TM, Willman CL, et al: Methods to detect P-glycoprotein associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-3020, 1996. (Pubitemid 26199746)
12. Leith CP, Kopecky KJ, Chen IM, et al: Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086-1099, 1999. (Pubitemid 29361842)
13. Den Boer ML, Zwaan CM, Pieters R, et al: Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia 11: 1078-1085, 1997. (Pubitemid 27345960)
14. Cole SP, Bhardwaj G, Gerlach JH, MacKie JE, et al: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654, 1992. (Pubitemid 23012438)
15. Scheffer GL, Wijngaard PL, Flens MJ, et al: The drug resistance-related protein LRP in the human major vault protein. Nature Med 6: 578-582, 1995.
16. Hoelzer D, Thiel E, Loffler H, et al: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71: 123-131, 1988. (Pubitemid 18050401)
17. Larson RA, Dodge RK, Burns CP, et al: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811. Blood 85: 2025-2037, 1995.
18. Annino L, Vegna ML, Camera A, et al: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 99: 863-871, 2002. (Pubitemid 34525547)
19. Chessells JM, Hall E, Prentice HG, et al: The impact of age on outcome in lymphoblastic leukaemia: MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 12: 463-473, 1998. (Pubitemid 28197568)
20. Czuczman MS, Dodge RK, Stewart CC, et al: Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: cancer and leukemia Group B study 8364. Blood 93: 3931-3939, 1999. (Pubitemid 29249842)
21. Westbrook CA, Hooberman AL, Spino C, et al: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood 80: 2983-2990, 1992. (Pubitemid 23004501)
22. Cimino G, Elia L, Rapanotti MC, et al: A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood 95: 96-101, 2000. (Pubitemid 30017231)
23. Tafuri A, Sommaggio A, Burba L, et al: Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leuk Res 19: 927-931, 1995. (Pubitemid 26037985)
24. Dhooge C, De Moerloose B, Laureys G, et al: P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 105: 676-683, 1999. (Pubitemid 29277025)
25. Marie JP, Zittoun R, Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592, 1991.
26. Del Poeta G, Stasi R, Aronica G, et al: Clinical relevance of P-glycoprotein expression in dc novo acute myeloid leukemia. Blood 87: 1997-2004, 1996. (Pubitemid 26074103)
27. Norgaard JM, Bukh A, Langkjer ST, et al: MDR1 gene expression and drug resistance of AML cells. Br J Haematol 100:534-540, 1998. (Pubitemid 28270489)
28. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroup with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group Study. Blood 89: 3323-3329, 1997.
29. Borowitz M, Schuster J, Land V, et al: Myeloid-antigen expression in childhood acute lymphoblastic leukemia. N Eng J Med 325: 1378-1382, 1991.
30. Masera G, Conter V, Rizzari M, et al: AIEOP non-B ALL trias. Int J Ped Haem Oncol 6: 101, 1999.
31. Musto P, Melillo L, Lombardi G, et al: High risk of early resistant relapse for leukemic, patients with presence of multidrug-resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 77: 50-53, 1991.
32. Futscher BW, Foley NE, Gleason-Guzman MC, et al: Verapamil suppresses the emergence of P-glycoprotein mediated multidrug resistance. Int J Cancer 16: 520-525, 1996. (Pubitemid 26176770)
33. Wuchter C, Karawajew L, Ruppert V, et al: Clinical significance of P-glycoprotein expression and function for response in induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 95: 711-721, 2000. (Pubitemid 30617105)